香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 佈 全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 WAI YUEN TONG MEDICINE HOLDINGS LIMITED （位 元 堂 藥 業 控 股 有 限 公 司* （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：897） 盈利警告 本公佈由本公司根據上市規則第13.09條及證券及期貨條例第XIVA部項下內 幕消息條文（定 義 見 上 市 規 則）而 作 出。 董 事 會 謹 此 知 會 本 公 司 股 東 及 潛 在 投 資 者，基 於 對 本 集 團 於 報 告 期 間 之 未 經 審 核 綜 合 管 理 賬 目 草 稿 之 初 步 審 閱 及 董 事 會 目 前 可 得 之 資 料，本 集 團 預 期將錄得於相應期間母公司擁有人應佔溢利約23,700,000港元減少至於報告 期間母公司擁有人應佔溢利不多於約3,000,000港 元。 由 於 本 公 司 ...

(於百慕達註冊成立之有限公司) (股份代號 : 897) 董事會會議通告 香港交易及結算所有限公司及香港聯 合交易所有限公司對本通告之 內容概不負責，對其準確性或完整性亦不發表 聲明，並明確表示， 概不對因本通告全部或任何部分內容而 產生或因依賴該等內容而引致 之任何損失承擔任何責任。 WAI YUEN TONG MEDICINE HOLDINGS LIMITED (位元堂藥業控股有限公司* ) 於本通告刊發之日，董事會包括執行董事鄧清河先生、鄧蕙敏女士及 羅敏儀女士；及獨立非執行董事李家暉先生、薛永恒教授及陳永光 教授。 * 僅供識別 Wai Yuen Tong Medicine Holdings Limited（位 元 堂 藥 業 控 股 有 限 公 司 * ） （「 本公司 」）董事會（「 董事會 」）謹此公佈，本公司將於二零二五年 十一月二十四日（星期一）舉行董事會 會議，旨在考慮及通過（其中 包括）本公司及其附屬公司截至二零二五年九 月三十日止六個月之 中期業績，以及考慮派發中期股息（如有）。 承董事會命 WAI YUEN TONG MEDICINE HOLDINGS LIMITED (位元 堂藥業 ...

Core Viewpoint - The ownership transfer of Shankai Intelligent has been terminated due to the failure to obtain necessary approvals from the relevant state-owned asset regulatory authorities, raising questions about the underlying reasons for the termination and the company's information disclosure practices [1][2][3]. Group 1: Ownership Transfer Details - Shankai Intelligent announced the termination of the ownership transfer agreement on November 7, citing the lack of approval from state-owned asset regulatory authorities as the reason [2][3]. - The agreement stipulated that the transfer would only take effect upon approval from the shareholders' meeting and the relevant regulatory bodies, which has not been fulfilled [2][3]. - The transfer was initially approved by the local state-owned asset supervision authority, but further approvals from higher-level authorities were required, leading to confusion regarding the approval process [3][4]. Group 2: Key Individuals and Events - Li Yajun, a key figure in the ownership transfer, was detained a month prior to the announcement, which has raised concerns about the legitimacy of the transaction [4][5]. - Li Yajun played a significant role in the transaction, holding a board position at Changjiang Aerospace and being involved with major shareholders [5][6]. - The sudden termination of the ownership transfer followed a report highlighting Li Yajun's situation, indicating a potential link between his legal troubles and the transaction's collapse [1][6]. Group 3: Market Reactions and Stock Performance - Following the announcement of the termination, Shankai Intelligent's stock price experienced a significant drop, with a peak decline of 6% and a closing drop of 1.08% [6]. - Prior to the suspension of trading, the stock had seen a notable increase of 38% over 13 trading days, raising suspicions among investors regarding the timing of the price movements [7][8]. - New shareholders emerged just before the stock price surge, but they disappeared from the top ten shareholders list in the subsequent quarterly report, indicating potential volatility in shareholder composition [8][9].

Core Viewpoint - The ownership transfer plan of Shankai Intelligent (300897) is facing difficulties due to the recent issues surrounding key figure Li Yajun, who is linked to the buyer, Hubei Changjiang Aerospace Technology Investment Co., Ltd. [1][6] Group 1: Ownership Transfer Plan - In July 2025, Shankai Intelligent announced a plan to transfer control to Hubei Changjiang, which would make the Wuhan New District State-owned Assets Supervision and Administration Commission the new controlling entity [1][2]. - The transfer agreement states that Changjiang Aerospace will acquire a 19.70% stake at a price of 20.7 yuan per share [2][3]. - Li Yajun, chairman of Shanghai Linxin Investment Management Co., is a significant figure in this transaction, holding key positions in both Linxin Investment and Changjiang Aerospace [5][6]. Group 2: Li Yajun's Situation - Li Yajun has reportedly been detained for over a month, which has not been disclosed by Shankai Intelligent [1][9]. - His absence has been noted in another company, Chongqing Road and Bridge, where he is unable to fulfill his duties as general manager due to personal reasons [7][10]. - The lack of updates regarding Li Yajun's status raises concerns about the stability of the ownership transfer plan [10]. Group 3: Financial Performance - Shankai Intelligent's financial performance has been declining, with a 28.96% year-on-year drop in revenue to 236 million yuan in the first half of 2025, and a 48.36% decrease in net profit [11][12]. - The company's third-quarter report shows a 22.56% decline in revenue to 380 million yuan and a 59.34% drop in net profit [12]. - The company's accounts receivable reached 372 million yuan, which is 457% of the net profit, indicating potential issues with profit quality [12]. Group 4: Market Concerns - Prior to the suspension of trading, Shankai Intelligent's stock price experienced significant fluctuations, rising 38% over 13 trading days [13][14]. - New shareholders appeared in the top ten list just before the stock price surge, raising suspicions of insider trading [13][14]. - The combination of declining performance, unusual stock activity, and the high premium paid by state-owned entities for the acquisition has led to skepticism about the transaction [14].

致：香港交易及結算所有限公司 公司名稱: Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司) 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00897 | 說明 | 位元堂 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 60,000,000,000 | HKD | | 0.01 HKD | | 600,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 60,000,000,000 | HKD | | 0.01 HKD | | 600,000,000 | 本月底法定/註冊股本總額： HKD 600,000,000 FF301 股份發行人 ...

Core Viewpoint - The approval of the "Monkey Zao Chutian San" by the National Medical Products Administration marks a significant milestone for the company, indicating the successful implementation of the simplified registration policy for traditional Chinese medicine in Hong Kong and Macau [1] Company Summary - The company's stock, Bitian Tang (00897), rose by 11.36% to HKD 0.49, with a trading volume of HKD 2.5302 million [1] - The company’s flagship products include the "An Gong Niu Huang Wan" series, the classic "Yang Yin Wan," and the "Monkey Zao Chutian San," which has been a sales champion for ten consecutive years [1] Industry Summary - The approval represents the first product to be granted market access under the newly simplified registration policy for traditional Chinese medicine, highlighting the effectiveness of regulatory changes in the industry [1]

Core Viewpoint - The approval of the "Monkey's Paw Phlegm-Removing Powder" for mainland market entry marks a significant milestone for the company, reflecting the effectiveness of the simplified registration policy for traditional Chinese medicine in Hong Kong and Macau [1] Company Summary - The company's stock, Bit Yuan Tang (00897), rose over 11%, reaching a price of 0.49 HKD with a trading volume of 2.53 million HKD [1] - The company’s flagship products include the "An Gong Niu Huang Wan" series, the classic "Yang Yin Wan," and the "Monkey's Paw Phlegm-Removing Powder," which has been a sales champion for ten consecutive years [1] Industry Summary - The approval of the product is the first instance of a traditional Chinese medicine being granted entry into the mainland market under the new simplified registration policy, indicating a positive trend for the industry [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司) 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00897 | 說明 | 位元堂 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 60,000,000,000 | HKD | | 0.01 HKD | | 600,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 60,000,000,000 | HKD | | 0.0 ...

Group 1 - The core point of the article highlights that on September 16, Bitland (00897) transferred shares from BNP Paribas to Bank of Communications (Hong Kong), with a market value of HKD 300 million, accounting for 71.16% of the shares [1] - Bitland reported its financial results for the year ending March 31, 2025, showing revenue from continuing operations of approximately HKD 745 million, a year-on-year decrease of 4.9% [1] - The company achieved a profit attributable to equity holders of HKD 7.1 million, marking a turnaround from a loss in the previous year, with earnings per share of HKD 0.63 [1]

（原标题：位元堂(00897)股东将股票由法国巴黎银行转入交通银行(香港) 转仓市值3亿港元） 位元堂公布的截至2025年3月31日止年度业绩显示，公司持续经营业务收益约7.45亿港元，同比减少 4.9%；母公司拥有人应占溢利710万港元，同比扭亏为盈；每股盈利0.63港仙。 智通财经APP获悉，香港联交所最新资料显示，9月16日，位元堂(00897)股东将股票由法国巴黎银行转 入交通银行(香港)，转仓市值3亿港元，占比71.16%。 ...